/stocks — the workspaceLOADING
All KZIA SEC filings, by type → · Earnings date & implied move · Search inside filings
KZIA is not among the 142 companies we ingest every day, so it is not in the fundamentals screener or the size and group lists built from it. This page reads its SEC filings when the page is built. Ask us to add it: we keep a count per ticker and nothing about you.
KAZIA THERAPEUTICS LTD (KZIA) is a pharmaceutical preparations company. Fundamentals from SEC filings; prices are end-of-day.
Every filed figure on this page is free to read, dated and sourced; no column is held back for a paid plan. Each section with figures says what date they are true as of and where they come from.
What’s behind KZIA’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has KZIA been issuing shares? Offering history →
Volume against its own history: 27% of its last 252 sessions were lighter than the last one, the 2026-11-09 session. End-of-day bars (Databento). Volume detail
This company reports under IFRS, so its figures come from the ifrs-full taxonomy rather than US GAAP. Year to 2025-06-30, from the 20-F filed 2025-11-07, in AUD as filed and never converted. Annual figures only: half-years on 6-K are not joined into a trailing year.
| Revenue | 42,000 AUD 2.3M AUD a year earlier (2024-06-30) | ifrs-full Revenue |
| Gross profit | Not tagged: the newest annual report files no GrossProfit for this year in AUD, so no figure is shown. | |
| Operating profit | Not tagged: the newest annual report files no ProfitLossFromOperatingActivities for this year in AUD, so no figure is shown. | |
| Net income | -20.7M AUD -26.8M AUD a year earlier (2024-06-30) | ifrs-full ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | -0.04 AUD a share -0.10 AUD a share a year earlier (2024-06-30) | ifrs-full DilutedEarningsLossPerShare |
| Total assets | 6.1M AUD 21.6M AUD a year earlier (2024-06-30) | ifrs-full Assets |
| Total liabilities | 14.4M AUD 31.6M AUD a year earlier (2024-06-30) | ifrs-full Liabilities |
| Shareholders’ equity | -8.3M AUD -10.0M AUD a year earlier (2024-06-30) | ifrs-full EquityAttributableToOwnersOfParent |
| Cash and equivalents | 4.3M AUD 1.7M AUD a year earlier (2024-06-30) | ifrs-full CashAndCashEquivalents |
| Operating cash flow | -13.3M AUD -9.6M AUD a year earlier (2024-06-30) | ifrs-full CashFlowsFromUsedInOperatingActivities |
| Capital spending | Not tagged: the newest annual report files no PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities for this year in AUD, so no figure is shown. | |
| Share-based payment | 653,000 AUD 533,000 AUD a year earlier (2024-06-30) | ifrs-full AdjustmentsForSharebasedPayments |
Not shown for IFRS filers: trailing-twelve-month figures, the F, Z and M scores, market cap and per-ADS figures. The coverage boundary, and why
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as KZIA tagged it, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on KZIA plus an auto-SWOT, built from KZIA's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts, a bull, a bear, a risk manager, and a PM, debate KZIA using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Ask about KZIA’s revenue, earnings, valuation, filings, insiders or Congress trades. Answers come only from the numbered evidence the research brief uses, each citing the items it rests on. A question about one figure is answered by code, free. One that puts figures together is 1 generation (Pro). A question about whether to buy, sell or hold, how much, or where the price goes gets a refusal.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Closes only, split-adjusted. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
Daily closes from 2024-07-01 through 2026-11-09, 593 sessions, split-adjusted (1 split applied). No direction, pattern, entry, target or overbought label: these are measurements. Filings dated on the move days are in KZIA’s filings; the chart with studies draws every figure.
Written by code from 593 end-of-day bars through 2026-11-09. Written by code from the data on file, not by a model. Information, not investment advice: it describes the security and recommends nothing to anyone.
Projected from KZIA's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentKZIA files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
On file for KZIA from Nov 10, 2026 to Nov 23, 2026: filing deadline (below).
| Event | Result |
|---|---|
| Earnings date | nothing in the window. No date in the window: no regular report cadence in the filings. |
| Filing deadline | on file. Past due: the 20-F for the fiscal year ending Jun 30, 2026, due four months after it, fell due Nov 2, 2026 and is not in the filings list. A notice of late filing (NT 20-F) was filed Nov 2, 2026. Newest periodic report on file: the 20-F for the period ending Jun 30, 2025, filed Nov 7, 2025. filing list on EDGAR |
| Ex-dividend date | not covered. Not checked. This attestation does not cover ex-dividend dates. |
This records what these sources returned when they were read. It is not a forecast: a company can announce an event at any time, and ex-dividend dates are not covered. Window 2026-11-10 to 2026-11-23, Eastern dates. Deadlines follow SEC Rules 13a-1 and 13a-13 and Form 20-F, moved past weekends and federal holidays by Rule 0-3.
1 of the 2 checks that ran found nothing new for KZIA; 1 found something. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
No fair value band on this page build. No annual filing figures reached the estimators, either because the SEC read did not finish or because KZIA has not filed annual figures yet. That is a statement about the read, not about KZIA’s value. The page rebuilds daily.
Every refusal recorded for KZIA → · How often we decline, and why →
Group: Pharmaceutical Preparations, the SEC industry code KZIA files under. 10 companies in our stored table file under it.
| Metric | KZIA | Group median | 25th to 75th percentile | Where KZIA sits |
|---|---|---|---|---|
| Net marginnet income divided by revenue, same fiscal year | not placed | 21.4%⊙INFERENCE — derived by arithmetic SourceNet margin across the 10 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. A group prints from 6 companies with the figure. | 13.0% to 28.4% | KZIA has no annual report in the stored table yet, so it has no figure to place. |
| Free cash flow marginoperating cash flow less capital expenditure, divided by revenue, same fiscal year | not placed | 20.9%⊙INFERENCE — derived by arithmetic SourceFree cash flow margin across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's operating cash flow less capital expenditure, divided by revenue, same fiscal year, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 16.7% to 26.7% | KZIA has no annual report in the stored table yet, so it has no figure to place. |
| Return on equitynet income divided by stockholders’ equity at the fiscal year end | not placed | 32.9%⊙INFERENCE — derived by arithmetic SourceReturn on equity across the 9 companies filing under SEC SIC "Pharmaceutical Preparations" in our stored table As offiscal years ended 2025-12-28 to 2025-12-31 HowEach company's net income divided by stockholders’ equity at the fiscal year end, from its newest annual report as stored. The median is the middle value; the 25th to 75th percentile is the middle half, linear between ranks. 1 of the 10 companies in the group lack the figure and are not counted. A group prints from 6 companies with the figure. | 12.5% to 38.2% | KZIA has no annual report in the stored table yet, so it has no figure to place. |
One filed metric per row, each a ratio of two figures from the same annual report; no composite and no grade. Percentile is the share of the group’s other companies with a lower figure. A group prints from 6 companies with the figure. The group is drawn from our stored table (the S&P 500 issuers and the companies we cover, each with its newest annual report read), not from every filer in the class. Industry pages show the same medians by group.
Head office: Sydney, Australia
Source: the cover page of KAZIA THERAPEUTICS LTD’s 20-F filed 2025-11-07, on EDGAR. Filings checked 2026-11-10. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
No tracked institution reported a position in KZIA in the latest 13F round.
No open-market Form 4 buys or sells reported for KZIA in the last ~6 months.
No lawmaker has disclosed a trade in KZIA under the STOCK Act.